Imaging in Semaglutide Study

NCT07695454 · Not yet recruiting

Last updated 2026-07-13

This clinical trial is testing how semaglutide, a medication, affects muscle health in people with type 2 diabetes who also have a BMI over 30, using a special imaging technique called phosphorous MR spectroscopy.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 10 people Planned (estimated).

Who can join Ages 45–75 · all sexes

Timeline Started 2026-07 · est. completion 2027-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07695454 ↗

Description as written by the study sponsor.

In this preliminary observation study, the investigators will assess muscle function in terms of muscle strength and leverage imaging (MRI) and spectroscopy (31P-MRS) based techniques to assess longitudinal changes in muscle volume, quality and metabolic function in patients with T2D and obesity prescribed to semaglutide therapy. The patients will be evaluated at three time points: 1) baseline, 2) 3-month and 3) 6-month after the therapy. These longitudinal changes will then be compared and correlated with changes in physical measurements such as BMI and patient reported outcome measures (PROMs). The primary aim of our study is to investigate the longitudinal effects of semaglutide therapy on patients with T2D and obesity, on skeletal muscle strength, muscle volume, quality and metabolic function.

Treatments tested

31P-MRS and MRI Radiation

31P-MRS and MRI for patients with Type 2 Diabetes and obesity prescribed to semaglutide therapy

Main thing measured	Effects of semaglutide therapy on patients muscle mitochondrial function as quantified using phosphorous MR spectroscopy.
Sponsor	The Cleveland Clinic
Conditions studied	Type 2 Diabetes, BMI Greater Than 30
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07695454 ↗